{"id":52329,"date":"2022-12-23T13:02:15","date_gmt":"2022-12-23T12:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/"},"modified":"2022-12-23T13:02:15","modified_gmt":"2022-12-23T12:02:15","slug":"legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/","title":{"rendered":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB\u2019s Proprietary ADC Platform<\/b>\n<\/li>\n<li>\n<b>LCB Eligible to Receive up to USD 1.25 billion<\/b>\n<\/li>\n<\/ul>\n<p>DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ADC?src=hash\" target=\"_blank\" rel=\"noopener\">#ADC<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.legochembio.com%2Findex.php%3Flang%3De&amp;esheet=53128857&amp;newsitemid=20221223005034&amp;lan=en-US&amp;anchor=LegoChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2e1ce3b1d5add34f2f5ef434b5f05bc1\" rel=\"nofollow noopener\" shape=\"rect\">LegoChem Biosciences, Inc.<\/a> (\u2018LCB\u2019) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, whereby it granted Amgen rights to research, develop, and commercialize ADCs directed against up to 5 targets selected by Amgen based on LCB\u2019s proprietary ConjuAll ADC technology.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/5\/LegoChemBio_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg\"><\/a><\/p>\n<p>\nUnder the terms of the agreement, LCB is eligible to receive up to USD 1.25 billion including upfront, development and commercial milestone payments, and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.\n<\/p>\n<p>\nLCB\u2019s clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs. It overcomes the limitations associated with conventional technologies that produce heterogeneous ADCs with its greater potency, safety and stability, and enables the development ADCs with a wider therapeutic window and improved manufacturability.\n<\/p>\n<p>\n&#8220;Amgen has a proven track record of bringing transformative medicines to market, and we are pleased that they selected our ADC technology to integrate with their efforts to develop next-generation ADCs,\u201d said Yong-Zu Kim, LCB\u2019s President and CEO. \u201cThis licensing agreement demonstrates LCB\u2019s continued recognition as an industry-leading ADC player and further enhances our ability to innovate through global partnership as we build out our pipeline and accelerate our transformation into a fully-integrated oncology company.\u201d\n<\/p>\n<p>\nLCB has continued to build a robust ADC licensing deal flow with 12 transactions completed with a cumulative deal volume of over USD 5 billion.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nLegoChem Biosciences<b><br \/><\/b>Daeyoung Jeong<b><br \/><\/b>+82-42-861-0688<b><br \/><\/b><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;:&#x6a;d&#121;&#x40;&#108;&#x65;&#103;&#x6f;c&#x68;e&#109;&#x62;&#105;&#x6f;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6a;d&#x79;&#64;&#x6c;&#101;&#x67;&#x6f;c&#x68;&#101;&#x6d;&#98;&#x69;&#111;&#46;&#x63;&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB\u2019s Proprietary ADC Platform LCB Eligible to Receive up to USD 1.25 billion DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;#ADC&#8212;LegoChem Biosciences, Inc. (\u2018LCB\u2019) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52329","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB\u2019s Proprietary ADC Platform LCB Eligible to Receive up to USD 1.25 billion DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;#ADC&#8212;LegoChem Biosciences, Inc. (\u2018LCB\u2019) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-23T12:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates\",\"datePublished\":\"2022-12-23T12:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/\"},\"wordCount\":306,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221223005034\\\/en\\\/563858\\\/21\\\/LegoChemBio_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/\",\"name\":\"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221223005034\\\/en\\\/563858\\\/21\\\/LegoChemBio_Logo.jpg\",\"datePublished\":\"2022-12-23T12:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221223005034\\\/en\\\/563858\\\/21\\\/LegoChemBio_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221223005034\\\/en\\\/563858\\\/21\\\/LegoChemBio_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/","og_locale":"en_US","og_type":"article","og_title":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates - Pharma Trend","og_description":"LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB\u2019s Proprietary ADC Platform LCB Eligible to Receive up to USD 1.25 billion DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;#ADC&#8212;LegoChem Biosciences, Inc. (\u2018LCB\u2019) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-23T12:02:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates","datePublished":"2022-12-23T12:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/"},"wordCount":306,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/","url":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/","name":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg","datePublished":"2022-12-23T12:02:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221223005034\/en\/563858\/21\/LegoChemBio_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52329"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52329\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}